0PB Stock Chart & Stats
€5.05
€0.00(0.00%)
At close: 4:00 PM EDT
€5.05
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€4.03 - €5.20
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€473.71M
Enterprise Value€337.47M
Total Cash (Recent Filing)€93.90M
Total Debt (Recent Filing)€4.82M
Price to Earnings (P/E)19.2
Beta0.92
Next Earnings
Oct 29, 2026EPS Estimate
0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.54
Shares Outstanding51,620,068
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.28
Price to Sales (P/S)1.30
P/FCF Ratio7.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.36Price Target Upside6.04% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.33
Revenue Forecast (FY)€193.37M
Bulls Say, Bears Say
Bulls Say
NERLYNX Growth And Raised GuidanceImproving NERLYNX demand, higher product revenue, and raised full-year guidance indicate stronger commercial execution around Puma’s core therapy. If sustained, this can support recurring oncology revenue, fund development programs, and reinforce the company’s position in its approved HER2-positive breast cancer markets.
Debt-free Balance SheetEliminating debt materially improves financial flexibility by reducing mandatory cash obligations and interest-related pressure. The $93.9 million liquidity position gives Puma greater capacity to support commercialization and clinical development while providing a stronger buffer if operating results fluctuate.
Improved Profitability And Cash GenerationPositive profitability, strong gross margin, and cash flow that broadly converts reported earnings provide evidence of a more self-funded business model. This combination can support ongoing operations and investment without relying as heavily on external financing, provided recent cash performance remains consistent.
Bears Say
High Gross-to-net DeductionsLarge gross-to-net deductions reduce the revenue Puma ultimately retains from NERLYNX and make reported product growth less valuable than gross demand trends suggest. Persistent Medicaid exposure and rebates could constrain net sales, limit margin expansion, and increase sensitivity to payer mix.
Potential China Royalty ReductionA generic-triggered reduction in China royalties could permanently lower economics from the sublicense during the next several quarters. The risk matters because it would reduce recurring non-product income or profitability support without requiring an equivalent decline in operating costs.
Rising R&D Spending And Cash BurnAccelerating R&D investment can strengthen Puma’s future pipeline, but it also increases near-term cash consumption and execution requirements. Higher spending may pressure free cash flow and reduce the benefit of current NERLYNX profitability if clinical programs take longer to produce commercial returns.
Puma Biotechnology News
0PB FAQ
What was Puma Biotechnology’s price range in the past 12 months?
Puma Biotechnology lowest stock price was €4.03 and its highest was €5.20 in the past 12 months.
What is Puma Biotechnology’s market cap?
Puma Biotechnology’s market cap is €473.71M.
When is Puma Biotechnology’s upcoming earnings report date?
Puma Biotechnology’s upcoming earnings report date is Oct 29, 2026 which is in 17 days.
How were Puma Biotechnology’s earnings last quarter?
Puma Biotechnology released its earnings results on Aug 06, 2026. The company reported €0.143 earnings per share for the quarter, beating the consensus estimate of €0.036 by €0.107.
Is Puma Biotechnology overvalued?
According to Wall Street analysts Puma Biotechnology’s price is currently Undervalued.
Does Puma Biotechnology pay dividends?
Puma Biotechnology does not currently pay dividends.
What is Puma Biotechnology’s EPS estimate?
Puma Biotechnology’s EPS estimate is 0.08.
How many shares outstanding does Puma Biotechnology have?
Puma Biotechnology has 51,620,068 shares outstanding.
What happened to Puma Biotechnology’s price movement after its last earnings report?
Puma Biotechnology reported an EPS of €0.143 in its last earnings report, beating expectations of €0.036. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Puma Biotechnology?
Currently, no hedge funds are holding shares in DE:0PB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Puma Biotechnology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€5.36 (6.04% Upside)
€5.36 (6.04% Upside)
Blogger Sentiment
Neutral
DE:0PB Sentiment 50%
Sector Average 67%
Sector Average 67%
Technicals
SMA
Positive
20 days / 200 days
Momentum
97.50%
12-Months-Change
Fundamentals
Return on Equity
20.85%
Trailing 12-Months
Asset Growth
-1.12%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
0PB Company Deck
0PB Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights strong commercial momentum: meaningful QoQ and YoY increases in NERLYNX demand and bottle sales, a return to GAAP profitability in Q2, raised full-year revenue and net income guidance, and elimination of debt. These positives are tempered by pressure from high gross-to-net deductions (~28%), potential royalty reductions in China when generics gain share, rising R&D spend and increased quarter-over-quarter cash burn, and operational items like elevated DSO and a QoQ decline in new patient starts. On balance, the company appears to be in a strengthening commercial and financial position while managing identifiable near-term risks tied to deductions, international royalties, and increased investment in clinical programs.View all DE:0PB earnings summaries0PB Stock 12 Month Forecast
Average Price Target
€5.36
▲(6.04% Upside)
Technical Analysis
Heron Therapeutics
―
Voyager Therapeutics
―
Foghorn Therapeutics
―
Vor Biopharma
―
Tenaya Therapeutics
―